Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to help patients who have limited or inadequate treatment options live fuller, healthier lives. Founded in 2002 on the bold vision to turn scientific possibility into reality, Alnylam has a robust discovery platform and deep pipeline of investigational medicines, including several programs in late-stage clinical development. Patients are at the core of everything we do; their needs drive our discoveries and their stories further our commitment to delivering innovative therapies.
CLINUVEL PHARMACEUTICALS LTD is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore, with the UK acting as the EU distribution centre. For more information go to http://www.clinuvel.com